Keywords

Details

Category:

Other publications

Type:

Other publications

Title of issue:

Perceived Awareness of Clozapine associated with SocioDemographic status, clinical, and side effect profile among patients from Mental Health Hospital, Taif, Saudi Arabia strony 364 - 371

Publication year:

2022

DOI:

Digital Object Identifier (open in new tab) 10.30877/ijmh.9.4.2022.363-370

Bibliography: test

1. Ghaznavi S, Nakic M, Rao P, Hu J, Brewer JA, Hannestad J, Bhagwagar Z, Ferreri IG. Re-challenging with clozapine following neutropenia: Treatment options for refractory schizophrenia. Am J Psychiatry 2008;165:813-18. open in new tab
2. Bunney BS. Clozapine: a hypothesised mechanism for its unique clinical profile. Br J Psychiatry 1992;Suppl: (17):17-21. open in new tab
3. Gareri P, De-Fazio P, De-Fazio S, Marigliano N. Adverse effects of atypical antiphychotics in the elderly. Drugs Aging 2006;23(12):937-56. open in new tab
4. Schulte P. What is an adequate trial with clozapine? Therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin Pharmacokinet 2003;42:607-18. open in new tab
5. Amamou B, Essid N, Mrad A, Mhalla A, Gaha L. Resolution of Tardive Dyskinesia with Clozapine: A Case Report. Dual Diagn Open Acc 2016;1(19):10-2. open in new tab
6. Bernardi F, Del Zompo M. Clozapine in idiopathic Parkinson's disease. Comment Neurol 1989;39(9):1219- 21. open in new tab
7. Bonuccelli U, Ceravolo R, Maremmani C, Nuti A, Rossi G, Muratorio A. Clozapine in Huntington's chorea. Neurology 1994;44(5):821-3. open in new tab
8. Young CR, Bowers MB, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull. 1998;24(3):381-90. open in new tab
9. Lieberman JA, Safferman AZ, Pollack S. Clinical effects of Clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994;151:1744-52. open in new tab
10. Tracy JI, Monaco CA, Abraham G, Josiassen RC, Pollock BG. Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone. J Clin Psychiatry 1998;59(4):184-8. open in new tab
11. Fuller MA, Borovicka MC, Jaskiw GE, Simon MR, Kwon K, Konicki PE. Clozapine-induced urinary incontinence: incidence and treatment with ephedrine. J Clin Psychiatry 1996;57(11):514-8. open in new tab
12. Fabrazzo M, Prisco V, Sampogna G, Perris F, Catapano F, Monteleone AM, Maj M. Clozapine versus other antipsychotics during the first 18 weeks of treatment: a retrospective study on risk factor increase of blood dyscrasias. Psychiatry Res 2017;256:275-82. open in new tab
13. Siddiqui JA, Qureshi SF, Hamdi M, Alzahrani A. Leukocytosis associated with clozapine in elderly patient. J Geriatr Ment Health 2016;3:182-4. open in new tab
14. Nucifora FC Jr, Mihaljevic M, Lee BJ, Sawa A. Clozapine as a model for antipsychotic development. Neurotherapeutics 2017;14(3):750-61. open in new tab
15. Siddiqui JA, Qureshi SF, Ahmed Shawosh YB. Clozapine-induced massive hematemesis: A rare case report. Ann Indian Psychiatry 2019;3:171-2. open in new tab
16. Seftel A, Saenz de Tejada I, Szetela B, Cole J, Goldstein I. Clozapine-associated priapism: a case report. J Urol. 1992;147(1):146-8. open in new tab
17. Mishra B, Sahoo S, Sarkar S, Akhtar S. Clozapine-induced angioneurotic edema. Gen Hosp Psychiatry. 2007;29(1):78-80. open in new tab
18. Datta T, Solomon AJ. Clozapine-induced myocarditis. Oxf Med Case Reports. 2018;1:11-4. open in new tab
19. Green MF. Cognitive impairment, and functional outcome in schizophrenia, and bipolar disorder. J Clin Psychiatry 2006; 67(suppl 9):3-8. open in new tab
20. Schneider C. Corrigall R, Hayes D, Kyriakopoulos M, Frangou S. Systematic review of the efficacy and tolerability in the treatment of youth with early onset schizophrenia. Eur Psychiatry 2014;29:1-10. open in new tab
21. Dutt A, Grover S, Chakrabarti S, Kulhara P, Avasthi A, Basu D, Das PP. Effectiveness of Clozapine: a study from North India. Asian J Psychiatr.2010;3:16-9. open in new tab
22. Uddin MS, Arafat A. Profile of clozapine therapy: a cross sectional piloting in a tertiary care setting of Bangladesh. J Psychiatry Psychiatric Disord 2017;1(4):190-8.
23. Hassine H, Ouali U, Ouertani A, Jomli R, Nacef F. Clozapine-induced DRESS syndrome with multiple and rare organ involvement. Asian J Psychiatr 2017;28:146-7. open in new tab
24. Rogério dos SA, de Souza AS. The Maudsley Prescribing Guidelines in Psychiatry Igarss 2014:1-5. open in new tab
25. O'Brien CF, Jimenez R, Hauser RA, Factor SA, Burke J, Mandri D, Castro-Gayol JC. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo- controlled study. Mov Disord 2015;30(12):1681-7. open in new tab
26. Müller T. Valbenazine granted breakthrough drug status for treating tardive dyskinesia. Expert Opin Investig Drugs 2015;24:737-2. open in new tab
27. Umar MU, Isa AA, Abba AH. High dose pyridoxine for the treatment of tardive dyskinesia: clinical case and review of literature. Ther Adv Psychopharmacol 2016;6:152-6. open in new tab
28. Sobstyl M, Ząbek M. Deep brain stimulation for intractable tardive dystonia: Literature overview. Neurol Neurochir Pol 2016;50:114-2. open in new tab
29. Li X-B, Tang Y-L, Wang C-Y, de Leon J. Clozapine for treatment-resistant bipolar disorder: a systematic review. Bipolar Disord 2015;17(3):235-47. open in new tab
30. Ghaemi SN, Katzow JJ. The use of quetiapine for treatment-resistant bipolar disorder: A case series. Ann Clin Psychiatry 1999;11:137-40. open in new tab
31. Krarnlinger G, Branch BP, Health M. Adding lithium carbonate to carbamazepine: antimanic efficacy in treatment-resistant mania Acta Psychiatr Scand 1989;79(4):378-85. open in new tab
32. Vaidya NA, Mahableshwarkar AR, Shahid R. Continuation and maintenance ECT in treatment-resistant bipolar disorder. J ECT 2003;19:10-6. open in new tab
33. ************************************ Acknowledgements -Nil Conflict of Interest -Nil Funding -Nil

show (33) hide

Verified by:

No verification